Phase 1
18 Years
76 Years
18 Years
76 Years
Not Enrolling
Both
Leukemia, Lymphoma, Myeloma
Both
Leukemia, Lymphoma, Myeloma
Trial Information
Mucositis is a common side effect to chemotherapy and radiotherapy involving the formation
of erythema and ulcerative lesions in the mouth. Mucositis can be serious, resulting in pain
requiring interventions such as analgesic medications and the use of parenteral feedings.
Currently, no standard therapy is available to prevent or treat mucositis.
Inclusion Criteria
- Patients diagnosed with Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia and
Myeloma. - Eligible for treatment with radiation therapy and chemotherapy followed by
blood stem cell support.
Type of Study:
Interventional
Study Design:
Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To characterize the PK profile of 3 daily intravenous (IV) doses of rHuKGF before total body irradiation (TBI) / high-dose chemotherapy conditioning treatment and after PBPC transplantation
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Food and Drug Administration
Study ID:
20010182
NCT ID:
NCT00070616
Start Date:
December 2001
Completion Date:
Related Keywords:
- Leukemia
- Lymphoma
- Myeloma
- mucositis
- chemotherapy
- radiation therapy
- Leukemia
- Lymphoma
Name | Location |
|---|
